SREBF1 and metabolic dysfunction-associated steatotic liver disease: Also, the mRNA levels of PPAR-γ, SREBP-1c, ACC, FAS and LEP showed a 6 %, 7 %, 14 %, 16 % and 13 % decrease, respectively, in the low-dose group, compared with those of the positive control group (NAFLD rats) (Fig. 3a).